ATGAM is the purified, concentrated and sterile gamma globulin, primarily During processing, the drug is adsorbed with human erythrocyte stroma and with . Globulin [Equine] Sterile Solution. Brand Name Equivalent: Atgam® Product Insert “Preservative Information” indicates that this product does not contain. Brand names: Atgam, Lymphoglobuline, Thymogam up ↑ Antithymocyte globulin, horse ATG (Atgam) package insert (locally hosted backup).

| Author: | Kizilkree Dashura |
| Country: | Benin |
| Language: | English (Spanish) |
| Genre: | Automotive |
| Published (Last): | 1 November 2012 |
| Pages: | 455 |
| PDF File Size: | 17.63 Mb |
| ePub File Size: | 2.87 Mb |
| ISBN: | 478-5-54248-639-2 |
| Downloads: | 6775 |
| Price: | Free* [*Free Regsitration Required] |
| Uploader: | Voodoodal |
The risk to benefit ratio must be weighed. For full prescribing information, please visit www. Do not use highly acidic infusion solutions since these solutions may contribute to physical instability over time. Some studies have suggested an increase in the incidence of cytomegalovirus infection in patients receiving ATGAM. The effectiveness atgma the ATGAM therapy in the studies described below was evaluated by the hematological response and survival rates Table 3.
Infusion site erythema, Infusion site swelling, Pain. ATGAM is composed of antibodies that bind a wide variety of proteins on the surface of lymphocytes. Skin Testing To identify those at greatest risk of systemic anaphylaxis, skin testing potential recipients is strongly recommended before commencing treatment. Renal and urinary disorders: ATGAM is indicated for the management of allograft rejection in renal transplant patients; when administered with conventional therapy at the time of rejection ATGAM increases the frequency of resolution of the acute rejection episode [see Clinical Studies Use the in-line filter with all infusions of ATGAM to prevent the administration of any insoluble material that may develop in the product during storage.
A conservative, conventional approach would first employ epicutaneous prick testing with insfrt ATGAM.

Because reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate packave frequency or establish a causal relationship to drug exposure.
The maximum tolerated dose of ATGAM Sterile Solution would be expected to vary from patient to patient due to the biological nature of the product.
Antithymocyte globulin, horse ATG (Atgam)
ATGAM is indicated for the treatment of moderate to severe aplastic anemia in patients unsuitable for bone marrow transplantation [see Clinical Studies A systemic reaction such as a generalized rash, tachycardia, dyspnea, hypotension, or anaphylaxis precludes any additional administration of ATGAM. In this study, ATGAM was at least effective as standard therapy for treatment of acute allograft rejection.

Atgsm viral, Localized infection, Systemic infection Blood and lymphatic system disorders: It may appear colorless to faintly inseert or brown and is nearly odorless. Transplant Proc ; 13 1: Observe the patient continuously for possible allergic reactions throughout the infusions [see Warnings and Precautions 5.
Compatibility and Stability Once diluted, ATGAM has been shown to be physically and chemically stable for up to 24 hours at concentrations of up to 4 mg per mL in the following diluents: ATGAM is appropriately administered into a vascular shunt, arterial venous fistula, or a high-flow central vein using an in-line filter with ppackage pore size of 0.
Efficacy was evaluated as sustained improvement in peripheral blood counts within 3 months of entry into the study. Allergic reactions such as anaphylaxis have occurred in patients whose skin test is negative. Effects of antithymocyte globulin on cytomegalovirus infection in renal transplant recipients.
For storage conditions of diluted solution, see Dosage and Administration 2. Additional alternate-day therapy up to a total of 21 doses may be given.
Previously masked reactions to ATGAM may appear when the pacmage of corticosteroids and other immunosuppressants is being reduced. The predictive value of this test has not been insertt clinically.
The renal transplantation and aplastic anemia patients received a similar dosing regimen, and these data were pooled to wtgam the frequencies listed in Tables 1 and 2 below. Use of ATG for reversal of acute allograft rejection. If therapy with ATGAM is deemed appropriate following a locally positive skin test, treatment should be administered in a setting where intensive life support facilities are immediately available and a physician familiar with the treatment of potentially life threatening allergic reactions is in attendance.
Select the dose for an elderly patient with caution, starting at the low end of the dosage range [see Use in Specific Populations 8.
Musculoskeletal packzge connective tissue disorders: A randomized double-blind, placebo prospective, controlled study was conducted to compare the safety and efficacy of ATGAM and androgen oxymetholone; OXY immunosuppressive therapy with the combination of ATGAM, androgen OXY and an infusion of HLA mismatched bone marrow in patients with severe aplastic anemia who were not candidates for bone marrow transplantation.
Transplantation ; 28 6: Use only if the potential benefit justifies the risk.
Antithymocyte globulin, horse ATG (Atgam) | – A Hematology Oncology Wiki
Flank pain, Muscle rigidity, Myalgia, Pain in extremity. The safety of ATGAM has been evaluated in patients with renal transplant and patients with aplastic anemia. In this patient, atgsm administration of ATGAM was not associated with any signs of acute intoxication or late sequelae. To identify those at greatest risk, skin testing before treatment is strongly recommended.
Transplantation ; 31 2: The most commonly reported adverse events were rash, fever, arthralgias, chills, headache, myalgia and pruritus. ATGAM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
A maximum therapeutic tagam has not been established therefore the definition of overdose for ATGAM has not been clearly defined.
There was no difference in the patient survival rate between the two treatment groups. The usefulness of ATGAM has not been demonstrated in patients with aplastic anemia who are suitable candidates for bone marrow transplantation or in patients with aplastic anemia secondary to neoplastic disease, storage disease, myelofibrosis, Fanconi’s syndrome, or in patients known to have been exposed to myelotoxic agents or radiation. The use of ATGAM for the treatment of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation is based on data from three controlled studies.
The effect of ATGAM when administered in conjunction with standard therapy at the time of diagnosis of the first rejection episode was studied under two different protocols with cadaveric and living related renal transplant patients. Transplantation ; 29 2: Kidney enlargement, Kidney rupture, Renal failure acute Congenital, familial and genetic disorders:
